Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (339 reviews)

For research use only.

Catalog No.S1065 Synonyms: RG7321

339 publications

Pictilisib (GDC-0941) Chemical Structure

CAS No. 957054-30-7

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 339 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108750

PubMed: 33596424 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Food Chem Toxicol, 2021, S0278-6915(21)00034-X

PubMed: 33484789 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 552:23-29

PubMed: 33740661 ( click the link to review the publication )

Exp Hematol Oncol, 2021, 10(1):19

PubMed: 33663586 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Mol Cell, 2020, 80(1):164-174.e4

PubMed: 32877642 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )
Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO Mol Med, 2020, e11674

PubMed: 32558386 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(39):24427-24433

PubMed: 32929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31189-31197

PubMed: 33229547 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )

Sci Signal, 2020, 13(637):eaba8627

PubMed: 32576681 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

JCI Insight, 2020, 5(22)141832

PubMed: 33048843 ( click the link to review the publication )

Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100016

PubMed: 32984851 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4382-4392

PubMed: 32926124 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )
Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882967 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )
Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )
Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )
Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)e13441

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )
Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )
Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )
PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26384305 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )
Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )
Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )
PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )
J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MnHXT4lv[XOnIFHzd4F6		NWnGPGxmOSCq	MkDRSG1UVw>?	M{\BNmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyZHXseIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIEhf2m2aDDJR\|UxKG:oIECuNFA{KM7:TR?=	M132RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
Sf9	NHO0ZYFMcW6jc3WgRZN{[Xl?		NUHNWmZyOSCq	M{DDW2ROW09?	M3zPSWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBJOTB2Nz3SJI12fGGwdDDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGOxZYjwdoV{e2mwZzDwPFVidHCqYTD3bZRpKEmFNUCgc4YhOC5yMEOg{txO	NGLMUYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	MVTLbY5ie2ViQYPzZZk>		NGjRVJcyKGh?	MYXEUXNQ	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGgSVU1PS2NIH31eIFvfCCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[SC5aYToJGlEPTBib3[gNE4xODNizszN	NIj6XoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	MVjLbY5ie2ViQYPzZZk>		NEjnXoQyKGh?	MYHEUXNQ	NXX1U4lSUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	NGXwOpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
Sf9	MY\LbY5ie2ViQYPzZZk>		MXWxJIg>	MYLEUXNQ	NH;PblJKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHHsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhi	NVuyd5RPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVQ3PTRpPkG4O\|U1PjV2PD;hQi=>
MDA-MB-361	NHj6N4JHfW6ldHnvckBCe3OjeR?=		MknNNkBp	NIfjZpBFVVOR	M{[wUmlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvODJ6IN88US=>	NH74NGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1OFY2PCd-MUi3OVQ3PTR:L3G+
PC3	MUHGeY5kfGmxbjDBd5NigQ>?		NITNUHQzKGh?	NGrXcolFVVOR	MVvJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4udnWubDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODN5IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
U87MG	NXj0XYE5TnWwY4Tpc44hSXO\|YYm=		M4rIfVIhcA>?	MlvsSG1UVw>?	NV\MfGx6UW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDJR\|UxKG:oIECuNFQ3KM7:TR?=	M1;nN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
MDA-MB-361	M4jCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHvMVXE6PiCq	NHPxfpBFVVOR	MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlczKM7:TR?=	MmLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5NUS2OVQoRjF6N{W0OlU1RC:jPh?=
A2780	M4LFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlvQPVYhcA>?	NGHFNHNFVVOR	NWT4VHJPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	MlvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5NUS2OVQoRjF6N{W0OlU1RC:jPh?=
PC3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX25OkBp	MWPEUXNQ	MlLLTWM2OD1yLkK4JO69VQ>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd3NE[1OEc,OTh5NUS2OVQ9N2F-
U87MG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVrnPJNVQTZiaB?=	MWHEUXNQ	MVPJR\|UxRTBwOUWg{txO	M1nadFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{W0OlU1Lz5zOEe1OFY2PDxxYU6=
Sf9	M1;mWGtqdmG\|ZTDBd5NigQ>?		M131WFMxKG2rbh?=	MYjEUXNQ	M1zFdmlvcGmkaYTpc44hd2ZiaIXtZY4hWEl\|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDhcY92dnRib3[gRXRRKGOxboP1cYVlKHerdHigTWM2OCCxZjCwMlA1OiEQvF2=	NVTNZ5NyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFg{PDJpPkKyOVQ5OzR{PD;hQi=>
RAW 264.7	NWLKdIViU2mwYYPlJGF{e2G7		MYO5NEBucW5?	MYjEUXNQ	M1vvVGlvcGmkaYTpc44hd2ZiaIXtZY4hWEl\|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvOjl6IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2OEO0Nkc,OjJ3NEizOFI9N2F-
Sf9	MXvLbY5ie2ViQYPzZZk>		MUOxJIg>		NVXwXFhFUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2KndHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPGPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMUeg{txO	M3rqdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUSwOlQ2Lz5{M{W0NFY1PTxxYU6=
Sf9	MV\LbY5ie2ViQYPzZZk>		NWDaT2N3OSCq		MmrXTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4RmdHSjIHX4dJJme3OnZB?=	NUSzPYpxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDVpPkKzOVQxPjR3PD;hQi=>
Sf9	NGD6dlRMcW6jc3WgRZN{[Xl?		MofVNUBp		MkTHTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZB?=	NGrsWpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NFY1PSd-MkO1OFA3PDV:L3G+
Sf9	M3vQWmtqdmG\|ZTDBd5NigQ>?		M{PtVVEhcA>?		M{LZeWlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tidHCqYTDlfJBz\XO\|ZXS=	NH3NO5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NFY1PSd-MkO1OFA3PDV:L3G+
SKOV3	M2Tj[WtqdmG\|ZTDBd5NigQ>?	Mk[yNUDPxE1?	M3joZlEhcA>?	NFvxZolFVVOR	M2naNGlvcGmkaYTpc44hd2ZiUFmzT4FteGijIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25?	NHLjN3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2NFM1QCd-MkOzOlA{PDh:L3G+
MCF7	NEHNZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjNPGoyKM7:TR?=	NEnsPXQ6PiCq	M2nie2ROW09?	M1T2O2dKPTB;MD6wO\|AzKM7:TR?=	NGnHTmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2NFM1QCd-MkOzOlA{PDh:L3G+
SKOV3	NVrrSGtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqxJO69VQ>?	NHrRd2w6PiCq	MmC5SG1UVw>?	MUPHTVUxRTBwMUS3OkDPxE1?	NF7oS4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2NFM1QCd-MkOzOlA{PDh:L3G+
PC3	NIHDb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkPWO\|IhcA>?	M4\TfmROW09?	M1zKWmlEPTB;MD6yPEDPxE1?	M1TSUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUixO\|E1Lz5{MUm4NVcyPDxxYU6=
MCF7.1	NHLTWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfmTpFrPzJiaB?=	NGnwSVRFVVOR	NFrR[FBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKEiHUkKg[4Vv\SC5aYToJGlEPTBib3[gNE4zQCEQvF2=	M3TTblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUixO\|E1Lz5{MUm4NVcyPDxxYU6=
MCF7-neo/Her2	NFHQNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoTSO\|IhcA>?	M{TaO2ROW09?	Mn7CTWM2OD1yLkK5JO69VQ>?	M1PBZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[yPVA{Lz5{M{[2NlkxOzxxYU6=
MCF7-neo/Her2	NX3tWWNvU2mwYYPlJGF{e2G7				MWLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDTOFc{KHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	MoDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NkK5NFMoRjJ\|Nk[yPVA{RC:jPh?=
PC3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3zxW\|czKGh?	NHnmbXpFVVOR	NXTCVlFITUN3ME2wMlM1KM7:TR?=	NUXjXFZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5PFU3OzlpPkKxPVg2PjN7PD;hQi=>
MCF7.1	M2rIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmS0O\|IhcA>?	Mo\pSG1UVw>?	M4LUcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKG23dHHueEB4cXSqIFXDOVAhd2ZiMD6zPUDPxE1?	NGHkW3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm4OVY{QSd-MkG5PFU3Ozl:L3G+
PC3	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4T1eFczKGh?	MnjTSG1UVw>?	MoeyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiZHXmbYNq\W62IHnuJHBVTU5id3n0bEBKSzVyIH;mJFAvOzlizszN	M1nyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEWwOlY6Lz5{MEC1NFY3QTxxYU6=
MCF7.1	NFnsbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWi3NkBp	NVjSWVl4TE2VTx?=	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCLQ{WwJI9nKDBwM{Sg{txO	MmLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByNUC2OlkoRjJyMEWwOlY6RC:jPh?=
MCF7.1	NYjVSGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2\Hb\|czKGh?		MkHWSWM2OD1yLkeyJO69VQ>?	MmfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|NE[2OVYoRjJyM{S2OlU3RC:jPh?=
NCI-H1975	MVHDfZRwfG:6aXOgRZN{[Xl?		NUPuU5NNPzJiaB?=		MYTJR\|UxRTBwMkeg{txO	M{nVblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW5OVQ2Lz5{M{C1PVU1PTxxYU6=
H460	MkjjR5l1d3SxeHnjJGF{e2G7		M4jy[VczKGh?		NGTKWmZKSzVyPUCuPFch\|ryP	NYTKdXNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
HT-29	NXPjXW5oS3m2b4TvfIlkKEG\|c3H5		MmfqO\|IhcA>?		NXvtTVdXUUN3ME2wMlY3KM7:TR?=	NVvwRZNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
HepG2	M2fqTGN6fG:2b4jpZ{BCe3OjeR?=		MmHJO\|IhcA>?		MV\JR\|UxRTFizszN	Mm\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNUm1OFUoRjJ\|MEW5OVQ2RC:jPh?=
SGC7901	MmrzR5l1d3SxeHnjJGF{e2G7		MmHtO\|IhcA>?		MnzGTWM2OD1zLkig{txO	NGG2PIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
NCI-H226	NVPa[5FlS3m2b4TvfIlkKEG\|c3H5		M4TI[lczKGh?		Ml23TWM2OD1{Lkmg{txO	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNUm1OFUoRjJ\|MEW5OVQ2RC:jPh?=
A549	M{TUSWN6fG:2b4jpZ{BCe3OjeR?=		MmrJO\|IhcA>?		MoG2TWM2OD14Lkmg{txO	NVHX[ZVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOVk2PDVpPkKzNFU6PTR3PD;hQi=>
U87MG	M17CRmN6fG:2b4jpZ{BCe3OjeR?=		NGmzbFE4OiCq		MnXnTWM2OD15Lke3JO69VQ>?	NI\1SYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1PVU1PSd-MkOwOVk2PDV:L3G+
HBC4	NFKxemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI[wcVBtd2eJSUWwQU03NjB\|IF2=	NYjpeG1uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
BSY1	M3PxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nLSYxw\0eLNUC9MVYvQTBiTR?=	NGPSVYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HBC5	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7sc4dIUTVyPT22MlYxKE1?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MCF7	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDDcI9oT0l3ME2tO{4{OyCP	M1HOXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MDA-MB-231	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHsc4dIUTVyPT21MlQ3KE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
U251	M3fJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PSNYxw\0eLNUC9MVUvPTBiTR?=	MkDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF268	NV;QWmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rGPIxw\0eLNUC9MVUvOzliTR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF295	NIfTbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrjcI9oT0l3ME2tOk4{PyCP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
SF539	NVvmenZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTsc4dIUTVyPT22MlUxKE1?	MlHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SNB75	M1[1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\sc4dIUTVyPT23MlExKE1?	NF\McZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
SNB78	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\mfnZtd2eJSUWwQU03NjV{IF2=	M{HZTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCC2998	M4mwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGqwOYltd2eJSUWwQU03NjJ7IF2=	M3v4OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
KM12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPNNFQ5dG:pR1m1NF0uPS55NjDN	M2jUT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HT-29	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPsc4dIUTVyPT22MlMxKE1?	MnLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
HCT15	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLKdmVtd2eJSUWwQU03NjF{IF2=	Mln1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
HCT116	NUHH[5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3sc4dIUTVyPT21Mlg4KE1?	M13oblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
NCI-H23	NXr2TY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXScI9oT0l3ME2tOU44OyCP	M{HPOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
NCI-H226	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TldYxw\0eLNUC9MVYvOjFiTR?=	MmnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
NCI-H522	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mki2cI9oT0l3ME2tOk42QCCP	NGXz[WU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H483	NVjobo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLNRXo1dG:pR1m1NF0uPi53NjDN	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
A549	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfsc4dIUTVyPT22MlE2KE1?	Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS273	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\kcI9oT0l3ME2tOk41OyCP	MmS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS114	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHsc4dIUTVyPT21MlkzKE1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
LOXIMVI	NGW4NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDtcYNTdG:pR1m1NF0uPi5{OTDN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
OVCAR3	NYDzSm9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vTbIxw\0eLNUC9MVYvPzFiTR?=	MmTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPsc4dIUTVyPT21Mlc3KE1?	MkPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR5	M2TMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3SxVIxw\0eLNUC9MVYvOjZiTR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
OVCAR8	NY[3fYJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLucI9oT0l3ME2tOU44OyCP	M1rPd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SKOV3	NXzuT243T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHsWFV7dG:pR1m1NF0uPi53MjDN	NWOyZ5FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
RXF631L	NFG0bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;4cI9oT0l3ME2tOk45QCCP	NVzOWG1QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
ACHN	M1HLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXmcI9oT0l3ME2tOk4xPyCP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
St-4	M{\D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjmUGVtd2eJSUWwQU02NjV4IF2=	M4qyZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN1	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3lOGx3dG:pR1m1NF0uPy5yODDN	NW[5ZXlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN7	M2DCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzsc4dIUTVyPT22MlUxKE1?	NUOw[oFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN28	M2HNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzFc2Ztd2eJSUWwQU02NjV{IF2=	NF[xbFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN45	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfHcI9oT0l3ME2tOk42PSCP	NEXSPVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MKN74	NVL5PXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPtbHNpdG:pR1m1NF0uPi5yMjDN	NHqxb3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
DU145	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmS5cI9oT0l3ME2tOU45PSCP	NGTVbos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
PC3	M1nKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLsc4dIUTVyPT22MlY3KE1?	M1XzZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
ES5	M3jvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j0UWlEPTB;NUCuNlEhdk1?	NXHoOVJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HH	M{HkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTFzMT6wPEBvVQ>?	M3PwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	M4Cx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXyVVNKSzVyPUGxOE4{KG6P	MnewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1770	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7nUJNKSzVyPUGyN{45PiCwTR?=	Mnj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HuO9	NIfQO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHFS45NUUN3ME2yNFYvODJibl2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HAL-01	NGjDV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTJyNj63N{BvVQ>?	M1HDRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NOS-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf3XFFKSzVyPUKxNU45OiCwTR?=	NFWzOJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HGC-27	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD1WnM{UUN3ME2yNVIvPTdibl2=	NV;2WpBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NB69	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:0NpV2UUN3ME2yOFUvOjdibl2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RS4-11	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1H0NWlEPTB;Mk[xMlc3KG6P	M{fRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
DOK	NYrIeotNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\vTWM2OD1\|MEGuO{BvVQ>?	Ml;BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LB2241-RCC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnaR2NUUUN3ME2zNFMvQDRibl2=	MofGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1623	NYDU[HZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXHZm9CUUN3ME2zNFQvODhibl2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
YH-13	M{X4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTNyND6zNkBvVQ>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BPH-1	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTtPFlKSzVyPUOxOEBvVQ>?	NH\lTW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
AN3-CA	M{nmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2eyS2lEPTB;M{SwMlM4KG6P	Mn\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ES7	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHVTWM2OD1\|NEGuPVkhdk1?	NIfO[VI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MDA-MB-175-VII	M{PJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jPbmlEPTB;M{WyMlkzKG6P	NFjoRmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GAMG	NH2ySplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIGzeJBKSzVyPUO3NE45PSCwTR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CHL-1	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXQTWM2OD1\|N{iuOlUhdk1?	M3ywTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NB7	M4rwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTRVngyUUN3ME2zPFkvQDNibl2=	NYDMO4JtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MFE-280	NHSyblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHpdpNKSzVyPUSxPE4zKG6P	M2G4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HL-60	M1XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHKPGpKSzVyPUSyOU44PSCwTR?=	NFjzWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GCIY	NVLLb3B{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2WwOmlEPTB;NEOzMlghdk1?	M4TERlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MDA-MB-361	NWnxOG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{K3XGlEPTB;NEO5MlE{KG6P	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LXF-289	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3znU2lEPTB;NES4MlI4KG6P	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NBsusSR	NHHve21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjOPJBKSzVyPUS4PE45PSCwTR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KU-19-19	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DNZ2lEPTB;NUG2MlA4KG6P	M1\rSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A204	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTV{Mj6zN{BvVQ>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LB1047-RCC	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDjeHNKSzVyPUWyNk46OyCwTR?=	Ml3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-684	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlToTWM2OD13MkOuNVEhdk1?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PA-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInDVWRKSzVyPUWzNk41OSCwTR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MG-63	M{W4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfXVY1KSzVyPUW0NU4yOSCwTR?=	NI\yV2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BHT-101	NW[xbWdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjBclZKSzVyPUW0OE46PCCwTR?=	M{XzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NKM-1	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTV7Mz6wPUBvVQ>?	MnL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
T47D	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\wSWlEPTB;NUm3MlU3KG6P	M4jSdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MOLT-4	NHLzTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3n4b2lEPTB;NkKzMlYzKG6P	NV:4OIViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
IGROV-1	Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXK5VotqUUN3ME22N\|QvOzFibl2=	MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ES4	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTTTWM2OD14M{muOVQhdk1?	NInlV3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HuO-3N1	NGq1UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TEbWlEPTB;NkSyMlM5KG6P	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NEC8	M1y4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rvWWlEPTB;NkWzMlU4KG6P	NVrmcoRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HO-1-N-1	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTZ3OT6xO{BvVQ>?	NV\Gc\|JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EPCL-272H	NYPsTWZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTZ6Nz6yNUBvVQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
D-263MG	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTdzOD6xJI5O	M4\re\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MV-4-11	NXrtSGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTd{ND6zNUBvVQ>?	M3;jbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-NEP-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTd{NT65OEBvVQ>?	NGXYTJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW872	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG[5fotKSzVyPUeyO{45QSCwTR?=	NFz1XYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
P30-OHK	NVHufZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XLc2lEPTB;N{OwMlcyKG6P	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OMC-1	NV:5b3RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPWTWM2OD15NUGuNFkhdk1?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LoVo	NGW3e\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzyeHRlUUN3ME23O\|cvQSCwTR?=	NY\sU4l{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	M1n2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPZd5BKSzVyPUe5Ok4{PCCwTR?=	NEf2SIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
L-363	NYXkZ2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXFbmxKSzVyPUe5PE41OiCwTR?=	Mn;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ES8	NFuzVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnITWM2OD16MUCuOVIhdk1?	M{LJPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
697	NVXZOYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3G3fWlEPTB;OEOxMlU2KG6P	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HSC-3	NFHLNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTh\|OT61OEBvVQ>?	M4KyfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
H4	NWP0SZR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHqOIp6UUN3ME24OVAvQDVibl2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
QIMR-WIL	NYnNb2VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jGfGlEPTB;OE[1MlIhdk1?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
OAW-42	MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTh5Mj6xPUBvVQ>?	MonQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MCF7	M4XjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX62S5VkUUN3ME24PVgvPTlibl2=	NUDMbHk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SCC-25	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXaVnRKSzVyPUmxOE4yQSCwTR?=	M3;IWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1563	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfYSmNKSzVyPUmxOU46QSCwTR?=	NYHmWHBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OVCAR-5	NUfiW4wxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTl2MD6xO{BvVQ>?	M{\PRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HDLM-2	M2rzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1OzNGlEPTB;OUS5MlIhdk1?	NYrKZVlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NB5	NUnTcZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTtUmpsUUN3ME25OVYvPiCwTR?=	MkK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H292	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1r3fGlEPTB;OUe0MlMzKG6P	NHPafpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A101D	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLlXoRKSzVyPUm5NE4yQSCwTR?=	NXPPSGV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1648	NEjMXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXFTWM2OD17OUiuOVEhdk1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
EKVX	NEjwS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUOwWXl4UUN3ME2xMlAyOjlizszN	M2PkRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SW1710	NUKx[HA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGn3dppKSzVyPUGuNFQzOzNizszN	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
WM-115	NEHWOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjDb5NKSzVyPUGuNFY3PTZizszN	NWri[oJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-54	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEiyephKSzVyPUGuNFcxQDFizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TGBC24TKB	MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXyWoFKSzVyPUGuNFgxPDVizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H520	NYHUNVJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHacGdRUUN3ME2xMlA5QTZ5IN88US=>	MkD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
D-423MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvSTWM2OD1zLkC5PVYzKM7:TR?=	MoPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BFTC-905	NEfGOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLITWM2OD1zLkGzOFQ6KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HT	NVLIclllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7tVpJKSzVyPUGuNVM1PzhizszN	NV\GfXZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CTB-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXa[XNKSzVyPUGuNVQzQTNizszN	MoXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Hs-578-T	NInwdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHz0dJdKSzVyPUGuNVk2PjVizszN	NH:0Oos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HuH-7	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXPTWM2OD1zLkKwPVQ6KM7:TR?=	NGHzWFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LB996-RCC	NIDTXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnWzTWM2OD1zLkKyNVc4KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KYSE-270	NX\PWVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml76TWM2OD1zLkK5O\|M1KM7:TR?=	M{XxblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A4-Fuk	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DWeGlEPTB;MT6yPVk6OyEQvF2=	M1HlSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A498	NX2xWZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTY[nZ6UUN3ME2xMlMxPDd2IN88US=>	NHnxbVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-MEL-1	NWXwVnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFwM{C2O\|kh\|ryP	NHTYSow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
AU565	M2\lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jYdGlEPTB;MT6zNVg3OyEQvF2=	M1;p[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Saos-2	NYLEfZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTEcnZKSzVyPUGuN\|MzODVizszN	NF7FUoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A549	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4mzWWlEPTB;MT6zPVk4KM7:TR?=	MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
BFTC-909	NUCwfVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjsNJRKSzVyPUGuOFM{ODVizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MDA-MB-415	M13z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XacmlEPTB;MT60PFY6OiEQvF2=	NFe4OlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
639-V	M1TWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXW1Xlc5UUN3ME2xMlUxOjR3IN88US=>	M4Dne\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A704	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3uT5dKSzVyPUGuOVA4QDVizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PANC-03-27	M3XG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfXOJA3UUN3ME2xMlUyPDB6IN88US=>	NVrVV201RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-MEL-28	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwNU[wPFUh\|ryP	MlXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPPTWM2OD1zLk[wO\|Q3KM7:TR?=	NETPRnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HuP-T4	MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjWTWM2OD1zLk[wO\|c5KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\hTYNKSzVyPUGuOlEzPyEQvF2=	NF7oXm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
EFM-19	M2j6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnqcm1KSzVyPUGuOlE5OSEQvF2=	NUTNcm91RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
G-401	NH;0OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrIfm5KSzVyPUGuOlIyPjRizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
D-566MG	NVuz[nRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTFwNkK1N{DPxE1?	MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
JVM-3	M2nrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjDUpBKSzVyPUGuOlQ5PzVizszN	MlTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TK10	NH;zZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3K1SmlEPTB;MT62O\|A5OyEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BT-20	NUHRS4xpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLiTWM2OD1zLk[4PVAzKM7:TR?=	MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EGI-1	M17RfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\rPIdjUUN3ME2xMlg1PzBzIN88US=>	NVjzfJJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EW-16	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LOW2lEPTB;MT64OVE5OiEQvF2=	NFz4TJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H2228	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{eyW2lEPTB;MT64OVIxOyEQvF2=	NE\lcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BB49-HNC	NFHVVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTTTWM2OD1zLki4OlkzKM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
G-402	NILHN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLqRop7UUN3ME2xMlg6Pzl5IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H526	M4f5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFwOUGzPUDPxE1?	M3vaWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ME-180	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTFwOUO0O\|ch\|ryP	MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PFSK-1	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrjXGgyUUN3ME2xMlk1PDV6IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TYK-nu	NH31SXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXNTWM2OD1zLkm1PFI{KM7:TR?=	MlLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HOS	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTQTWM2OD1zLkm3PVQ5KM7:TR?=	MoHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
T98G	NFXZS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTFwOUmwNFYh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SK-MES-1	NXLYWGM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLCd4htUUN3ME2yMlAyOzN{IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SNB75	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJwMEG1OFEh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LAMA-84	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXv5ZWtjUUN3ME2yMlAzPjh7IN88US=>	NVnubGdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-39	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17pc2lEPTB;Mj6wN\|I5KM7:TR?=	M2rpSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LOXIMVI	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;YUGlEPTB;Mj6wOFA5PCEQvF2=	M4LMVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NH-12	NIDnR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;4TWM2OD1{LkC1OFI1KM7:TR?=	NYnIeHl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1048	NXLGNGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nldGlEPTB;Mj6xNFUzKM7:TR?=	M1nYTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnPbXNFUUN3ME2yMlEyODBzIN88US=>	NF[xOGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-N87	M2\qWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3SU4VKSzVyPUKuNVM{QDRizszN	MlXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CHP-212	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHOwZYRKSzVyPUKuNVg1PDJizszN	NEHzeYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HCC1419	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIm0c\|hKSzVyPUKuNlEyOTVizszN	M4jOb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ES1	NHLIVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTJwMkGzNlYh\|ryP	NXe5XpJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H2030	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXJWpN{UUN3ME2yMlI1OTJ\|IN88US=>	M4HIPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
EW-22	NVjmZ21NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTJwMkWwOlch\|ryP	NIrvNGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A431	M4n5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDyTWM2OD1{LkK3N\|U1KM7:TR?=	NHrGPWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SF126	NGTsW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIGzb3ZKSzVyPUKuN\|A3OjVizszN	M{\OWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SF295	NVXMZVd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnSSJJKSzVyPUKuN\|E2OjRizszN	M1;r[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
D-502MG	NXjxd4Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\we5FOUUN3ME2yMlMzPDZzIN88US=>	NF3vSXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HCC2157	M3zmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFP2cYlKSzVyPUKuN\|I6OjdizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
D-283MED	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3FTWM2OD1{LkO1PVI3KM7:TR?=	MnTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SNU-423	NHfOPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz6RmlKSzVyPUKuOFAyPzFizszN	M1TtTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-LU-1	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTJwNES1PFYh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
22RV1	NIiydJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJwNEW2NVch\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SW1088	NV\BRpI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\ZbmlEPTB;Mj60PVIyOyEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HT-3	NFHpemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPuTWM2OD1{LkS5NlU6KM7:TR?=	M3v5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1666	NFHkNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTJwNUGxNFQh\|ryP	NXTI[GpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EM-2	M1XJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXv3OXEyUUN3ME2yMlUyOTZ7IN88US=>	M{HMTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SNU-449	NETOVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYL4U3Q5UUN3ME2yMlU4ODF2IN88US=>	M2LFblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
786-0	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLzTWM2OD1{LkW5NlM5KM7:TR?=	Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SKG-IIIa	NFi0dW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDFTWM2OD1{Lk[1PVM6KM7:TR?=	M2jKcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MEL-HO	MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLOR257UUN3ME2yMlY4PjN2IN88US=>	NU\M[pJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	NGXxXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnxTWM2OD1{Lk[5NlY4KM7:TR?=	M1jFO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MKN7	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLJTWM2OD1{LkewO\|U1KM7:TR?=	NIXqe2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
5637	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTJwN{GwN\|Uh\|ryP	NHrhcGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HOP-92	M2O4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fpdGlEPTB;Mj63OFcyPyEQvF2=	MkfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MDA-MB-157	M2j5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnr3TWM2OD1{LkiyNFI{KM7:TR?=	NE[5Sok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NB12	M2DT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jBT2lEPTB;Mj64OFkyPCEQvF2=	NFTwS3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DMS-273	NWnRO2RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnyfpFVUUN3ME2yMlg3PDdizszN	MkO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCC70	M2TqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJwOE[1PFkh\|ryP	MnvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
YKG-1	M{HrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXBZnZKSzVyPUOuNFM4QDdizszN	M2PsXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H28	NWnZcJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrkTWM2OD1\|LkC1NlkyKM7:TR?=	NEnjUmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HN	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HHcmlEPTB;Mz6wOlY{PiEQvF2=	M3TUO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HT-1080	M{f5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFW5NHFKSzVyPUOuNFg3ODZizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HPAF-II	MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;3NoJxUUN3ME2zMlExODZ6IN88US=>	NFH0T\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
U-2-OS	M4\NWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHaTWM2OD1\|LkGzO\|gzKM7:TR?=	NUiwbJNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SNU-387	M4HGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DYTmlEPTB;Mz6xOlM3PCEQvF2=	M{DoOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Becker	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTNwMU[4NFgh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BHY	NH:yVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLaVWtnUUN3ME2zMlI2PTdzIN88US=>	NFTKVlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HTC-C3	M1vzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnTN4VKSzVyPUOuNlk{PTJizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
M14	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYGxXmg3UUN3ME2zMlMxPjZ\|IN88US=>	MnzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COR-L23	M3TofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTofFM2UUN3ME2zMlM4Ojd7IN88US=>	Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
C32	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXvZZBCUUN3ME2zMlQyPTB6IN88US=>	M3n0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
Mewo	NHjzWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzSW2x2UUN3ME2zMlQzOTh{IN88US=>	Ml2xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TE-8	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MniwTWM2OD1\|LkS4NlU6KM7:TR?=	NXzlZ3lwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RPMI-2650	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7CTWM2OD1\|Lk[wOlM4KM7:TR?=	M370OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
AGS	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofZTWM2OD1\|Lk[yOFY1KM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
MZ2-MEL	M3q3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPHTZZZUUN3ME2zMlY3OTN6IN88US=>	NWq0Tmk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Calu-3	M4S3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LxRWlEPTB;Mz63NVI5PyEQvF2=	MlTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SJSA-1	NWTFd2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS4XGJ1UUN3ME2zMlcyOzF3IN88US=>	NF\4[HU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW962	Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDjTWM2OD1\|LkeyOlM3KM7:TR?=	Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
PC-14	M1vkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjNNHhKSzVyPUOuO\|MzOjJizszN	Mli3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW1573	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTNwN{WzOFgh\|ryP	M4TXflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
769-P	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTNwOEK3OFMh\|ryP	NGDGdW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KNS-62	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvCbYFuUUN3ME2zMlkzOzN6IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H747	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLRUGlKSzVyPUSuNFU3OzhizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LN-405	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rhZmlEPTB;ND6xOVczQCEQvF2=	NXTEcIdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OVCAR-8	MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHOTWM2OD12LkKyOVQ{KM7:TR?=	MoDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DMS-114	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\pTWM2OD12LkKzPFkyKM7:TR?=	M3TzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H2126	NUP1UIV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TrOGlEPTB;ND6yOFU2QCEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
TCCSUP	M2jUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\aTWM2OD12LkK0O\|g5KM7:TR?=	NGi2eoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-N-FI	M4HQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLld\|VMUUN3ME20MlI2OzN{IN88US=>	Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCE-4	M3HHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTRwMkexPVch\|ryP	M2nFZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
DK-MG	M1XF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjzTWM2OD12LkOwN\|kh\|ryP	NGXjZoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RO82-W-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrTTWM2OD12LkOyOVg1KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A2780	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTRwM{[2PFIh\|ryP	NFHiSFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
ETK-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXvTWM2OD12LkO3NFUzKM7:TR?=	NV7ERoZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
FADU	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXuyT2I3UUN3ME20MlM4PDZ5IN88US=>	NID3VVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-12T	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTRTWM2OD12LkSxOFE{KM7:TR?=	NX;JZ\|JMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
647-V	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;4R2dKSzVyPUSuOFQxOjJizszN	NFPMVVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TGBC1TKB	M13p[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjzbZIxUUN3ME20MlQ2OTF\|IN88US=>	MmLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LU-99A	M2DYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3GS5dKSzVyPUSuOFYxPiEQvF2=	NYDvfJhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAL-33	NGfZdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjzb3FsUUN3ME20MlUzPDV4IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LU-134-A	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fYVGlEPTB;ND61Nlc1PSEQvF2=	MmXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H1355	NXTYZWFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfhOmRKSzVyPUSuOVUyPDZizszN	NWexfnZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RPMI-7951	M4rCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTRwNUewNFIh\|ryP	NW\kUG1NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TE-1	NHz4cXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHwUG54UUN3ME20MlY3OTR\|IN88US=>	M3HkW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
OE33	NVm5NlBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLSTWM2OD12LkewOVEyKM7:TR?=	NIfVXHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-51	M2fJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jZfWlEPTB;ND63NVA5OiEQvF2=	NYHyTYRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW1783	NF\aVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nSeWlEPTB;ND63OVMxQCEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
BT-474	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ryfWlEPTB;ND63OlM5PCEQvF2=	Mkn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KYSE-520	MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTRwOEezPVIh\|ryP	NIL0emY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
8-MG-BA	NHnVTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPkbnM2UUN3ME20Mlg5PTV5IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
IA-LM	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\iNGlEPTB;ND65PVQ{PSEQvF2=	NVu4e2dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW954	NYDZS\|loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTRwOUm0OFMh\|ryP	MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RPMI-8226	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvYfZpKSzVyPUWuNFU1PjFizszN	M4DEdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MKN1	M37BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnl[4NKSzVyPUWuNFc6OjdizszN	NFT3SFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
A375	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnxTWM2OD13LkC5NlU3KM7:TR?=	NHvOWnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
8305C	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFr2PY9KSzVyPUWuNFk5QDdizszN	M{LsT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-62	NF;mdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXOZo93UUN3ME21MlE5OjV7IN88US=>	NH\QTlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NB10	M2H2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zMU2lEPTB;NT6yNlc1PCEQvF2=	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OC-314	NUT5e4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTVwM{e0OFQh\|ryP	M{[wbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
PSN1	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2riOmlEPTB;NT6zPFI5PiEQvF2=	M3nWXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
GR-ST	NFrlbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPRTWM2OD13LkO4N\|IzKM7:TR?=	M4nTPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
P12-ICHIKAWA	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfZOpBZUUN3ME21MlQxOSEQvF2=	NVvrNoJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1092	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLMUlFIUUN3ME21MlQyOTR6IN88US=>	NWrsNFM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SCC-4	NE\tc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTVwNEGzOVUh\|ryP	MoDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
TE-6	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWP5[4hnUUN3ME21MlQyQDF4IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DOHH-2	NIDMU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoeyTWM2OD13LkSyNlQ5KM7:TR?=	Mn\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW684	NFfzeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\JR2lEPTB;NT62OlM5PSEQvF2=	NYfMcIxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7sTWM2OD13Lk[4Olg1KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
UM-UC-3	NIT0eplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M176NmlEPTB;NT63NlI{OSEQvF2=	NG\vXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
LC-2-ad	NXf6e4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHGzO4FKSzVyPUWuO\|gzPTFizszN	NXHrV2c5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
PC-3	NYrn[5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TMdWlEPTB;NT65NVYyPSEQvF2=	MlvCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAN	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUK1WnZEUUN3ME21MlkzQDJizszN	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
ESS-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv4TWM2OD13Lkm3PFY6KM7:TR?=	M4HKUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
ATN-1	NYTPOWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLNVWY6UUN3ME22MlA2PTZ6IN88US=>	NXm2OHk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BxPC-3	M4LSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nZZmlEPTB;Nj6wPFIyQSEQvF2=	NYLMcXV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KYSE-150	NFXaR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T5SmlEPTB;Nj6xNlQ4PiEQvF2=	NWjnV2NMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RPMI-8866	NFnrWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTEbm1KSzVyPU[uNVkyPjNizszN	MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW780	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rjNmlEPTB;Nj6yNFQzKM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A388	M3i3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTXVI1WUUN3ME22MlI{OTF3IN88US=>	M2K4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1437	NWXZOpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnJUll7UUN3ME22MlI1ODd\|IN88US=>	NWK3WGlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1755	M2fQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:3Zm1FUUN3ME22MlM3PjF{IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LS-123	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTZwNEC1NlEh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CaR-1	NGLjRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzCTnlKSzVyPU[uOFY{PzNizszN	M1nzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RT-112	NGDre2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDUTWM2OD14Lk[wN\|M5KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CGT	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjDTWM2OD14LkezOlgyKM7:TR?=	MnuzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW626	NHPsOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\K[2lEPTB;Nj63N\|k1PiEQvF2=	NFnQSpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
AsPC-1	NGDoSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHP0TYNKSzVyPU[uO\|Q2ODdizszN	NVnjPWVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SBC-5	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTZwOUeyPVch\|ryP	M1G0b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SF539	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHFbpJJUUN3ME22Mlk6OzN\|IN88US=>	NV7vbI5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
TI-73	NYTXeXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjnTWM2OD15LkC2Nlg2KM7:TR?=	Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MHH-ES-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTdwMEe3OlIh\|ryP	NGDUUY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KYSE-510	NGT0[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjxXIRxUUN3ME23MlA5PDN{IN88US=>	Mn:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EW-1	M4\lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jHdWlEPTB;Nz6zOlk6PiEQvF2=	Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SK-OV-3	NVvwV3J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfke\|hKSzVyPUeuN\|k1OzJizszN	M2LGUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MC-IXC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzY[IdlUUN3ME23MlQyQTd{IN88US=>	NELqUoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HSC-2	M3u1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HEVGlEPTB;Nz60NlcxPSEQvF2=	NUfXWHZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H2342	NFXkN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTdwNUG0PUDPxE1?	NGDFZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H1792	Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7vWG5KSzVyPUeuOVE4OTFizszN	MoPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HT-1376	NHPvRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnS3TWM2OD15Lki3O\|c5KM7:TR?=	MnT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
EW-13	NFvzbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVSzUmN3UUN3ME23Mlg6QTd5IN88US=>	M1L0[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
no-11	NWGxU4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHTOFRKSzVyPUeuPVAyPzRizszN	MmC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
Daoy	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTdwOUSzNlEh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
COLO-800	NFHlT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPLTWM2OD16LkC0NVYzKM7:TR?=	NYq0RmV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
GB-1	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfEVmJrUUN3ME24MlA3PTZ3IN88US=>	MoTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SJRH30	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHiwXHdKSzVyPUiuNVU5PzhizszN	MofWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2291	NF\0N\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjkeZBKSzVyPUiuNlkyQDdizszN	NF7NSoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
J82	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoL2TWM2OD16LkK5OFkyKM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
NCI-H596	NGX6S4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzSRmdUUUN3ME24MlMyPDV\|IN88US=>	M3y5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RERF-LC-MS	M3H2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml31TWM2OD16LkO0PFU3KM7:TR?=	MlLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RH-18	M{eyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLHTWM2OD16LkO1NFQ3KM7:TR?=	NWTHbWNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SW48	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXoVVRKSzVyPUiuOVk1PTNizszN	NEXWS2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RD	NUTsUGFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrPTGpKSzVyPUiuOVk{QTFizszN	M4LUVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MS-1	M3j0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRThwNkGzPFch\|ryP	NWjxT5hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ES6	M3PBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRThwN{OxNVkh\|ryP	NFTYb249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
TE-12	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\ITpZyUUN3ME24Mlc4PTB3IN88US=>	NGn5Zmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DBTRG-05MG	M2H2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLJTWM2OD16LkmxNlE4KM7:TR?=	MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KINGS-1	MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYT0OnpyUUN3ME24MlkzQTN6IN88US=>	NH;JZlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HLE	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\hc5FKSzVyPUiuPVM4QDVizszN	NYnlbVRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MHH-NB-11	NUDFXoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DBcGlEPTB;OT6wNVg{QSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
U-87-MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHDdXp3UUN3ME25MlI1OzJzIN88US=>	NE\XSXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MN-60	M4HiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3IN4FQUUN3ME25MlI1PTR{IN88US=>	MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SAS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmf6TWM2OD17LkK1OVgyKM7:TR?=	MmTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H446	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTlwM{[xJO69VQ>?	M3zpTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
C-33-A	NYfCfI14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{e0VWlEPTB;OT60N\|k5QCEQvF2=	NULXTI85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
RXF393	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTaVJFIUUN3ME25MlQ4ODB{IN88US=>	M3vGXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CGTH-W-1	M2jOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofWTWM2OD17LkS5N\|g1KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
RCM-1	M2fOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTlwNkO4NFEh\|ryP	M2jlWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SN12C	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fNNGlEPTB;OT62OVM{QCEQvF2=	NETOWZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KLE	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoK5TWM2OD17LkewNFA6KM7:TR?=	NVTBRXU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EFO-21	NX;XTZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fzc2lEPTB;OT63O\|M5OiEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KYSE-70	M3HufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXCPHpKSzVyPUmuPFgxOTFizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
D-247MG	NWrr[WRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTTTWM2OD1zMD6wOVY5KM7:TR?=	M4LUZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MPP-89	M4flO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFyLkC5OFYh\|ryP	NHL3XZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RVH-421	NWj0PI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFyLkG1NFUh\|ryP	MkHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H460	NIXmdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mom5TWM2OD1zMD6yPFA3KM7:TR?=	NH3MXVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NOMO-1	M1HtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknHTWM2OD1zMD6zOVMzKM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DEL	NFHYeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TSdGlEPTB;MUCuN\|c6PCEQvF2=	NEfRblM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
HT55	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nxOmlEPTB;MUCuOlIxPSEQvF2=	M3vNc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MC116	M3vSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe5e2hKSzVyPUGwMlY3PTVizszN	NWHlfZZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BB30-HNC	M{LYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzTTW5KSzVyPUGwMlY3QSEQvF2=	NVfNW4VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
DJM-1	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFyLk[5OFkh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ZR-75-30	M4XVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFyLkm0OFEh\|ryP	MmPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
U-118-MG	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjLUZZKSzVyPUGwMlk5QTZizszN	NXjNS4dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MSTO-211H	NUnj[ZdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTFzLkC3NVYh\|ryP	NHjjUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW837	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jPZmlEPTB;MUGuNFk1QSEQvF2=	Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HuCCT1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fqfGlEPTB;MUGuNVI5OSEQvF2=	MoPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RCC10RGB	M4[2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDLTWM2OD1zMT6xN\|Uh\|ryP	M1PRV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NMC-G1	NWHVVmtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLzOGtCUUN3ME2xNU4yPDl\|IN88US=>	NEG0SHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
NCI-H650	NIL4W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFzLkO3PVQh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HEC-1	NV65b3NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTQTWM2OD1zMT60N\|I5KM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
DU-4475	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rSV2lEPTB;MUGuO\|M6OyEQvF2=	NIHq[HE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
DSH1	NVT0NWp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFzLke2NFYh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCC1569	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LxemlEPTB;MUGuO\|Y4QCEQvF2=	NYL0[W01RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
HCC1187	NXjXUHZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFzLki1PFgh\|ryP	NXvEVG93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EW-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTqeIVKSzVyPUGxMlk1PzRizszN	NV6ySXBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LB2518-MEL	M{fsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTF{LkC1PUDPxE1?	NHrGO249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KALS-1	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfobFBKSzVyPUGyMlg2PTNizszN	NHP2XJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
8505C	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTF{Lki4OUDPxE1?	NVvBO5lORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SK-N-DZ	NX7VfoNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlSyTWM2OD1zMz6wOFU{KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
CHP-134	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zwUWlEPTB;MUOuNVE2QCEQvF2=	MnH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCE-T	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jSdmlEPTB;MUOuNlM3PCEQvF2=	M{jPcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
LB-831-BLC	NUG3TmNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrncW05UUN3ME2xN{43OjR4IN88US=>	NYPlbJFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OVCAR-4	NFrRfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfITWM2OD1zMz62OVI1KM7:TR?=	Mk\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW756	NIHid29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PKbWlEPTB;MUOuO\|I1PiEQvF2=	NWTzXnZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OCUB-M	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rJN2lEPTB;MUOuPFE2PiEQvF2=	NETIcIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SW982	NFzUdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTF\|LkiyO\|Yh\|ryP	MlnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
DB	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPzSm1qUUN3ME2xN{45Ozh2IN88US=>	Mn3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
H-EMC-SS	NWG5OnNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml35TWM2OD1zMz65NVM6KM7:TR?=	NIjU[FY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
VMRC-RCZ	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Dre2lEPTB;MUSuNFAyPSEQvF2=	MnzKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
CAKI-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TjWmlEPTB;MUSuNFE{OiEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GI-1	M3TtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHJV2VRUUN3ME2xOE4xPjV6IN88US=>	NUj3Vop4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Ca9-22	NXe1Vm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXFTWM2OD1zND62NFU1KM7:TR?=	M{DWWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
TE-5	M1TQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVr4cIJvUUN3ME2xOE44OjB6IN88US=>	NWLxTmJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
EFO-27	M3vRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXL1d4ZpUUN3ME2xOE44PjJ{IN88US=>	M1zNR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-72	M3\3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnJdXNGUUN3ME2xOE44Pzh\|IN88US=>	NH;rPWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
GP5d	NFLyd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF3LkC0O\|Qh\|ryP	NYfPcIZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAS-1	NX3Dem82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTF3LkC2OkDPxE1?	Mo\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
A2058	NV;tdVR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGO1fo1KSzVyPUG1MlU3OzhizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PANC-08-13	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTF3Lk[4OVkh\|ryP	NYDaV2RRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
Detroit562	NIjzb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTF3LkmxN\|kh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
PANC-10-05	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTlTWM2OD1zNj6wPFIyKM7:TR?=	NF6zOnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KOSC-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPIXVFGUUN3ME2xOk4yOTJ3IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GT3TKB	NEjvbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHhR49KSzVyPUG2MlE6QDFizszN	M2DsPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KM-H2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXBdGt2UUN3ME2xOk4{PjR4IN88US=>	MlrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
LB771-HNC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWW5cXFVUUN3ME2xOk41PDJ{IN88US=>	NI\4d449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SF268	M13HN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PGd2lEPTB;MU[uOFUzKM7:TR?=	NGL2cWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
OE19	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HwZmlEPTB;MU[uOVI1KM7:TR?=	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MLMA	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1L2d2lEPTB;MU[uOVU4OSEQvF2=	Mmj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
MDA-MB-231	NYLmfZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LjUGlEPTB;MU[uO\|E{PiEQvF2=	M4HPblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
TGW	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoL4TWM2OD1zNj64NVAzKM7:TR?=	NFPFfYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
MDA-MB-453	M1m4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LCZWlEPTB;MUeuNFAxOyEQvF2=	NVfuSJJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SNU-C2B	NI[xVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;OTWM2OD1zNz6wNlM4KM7:TR?=	M1;4eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
A427	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3qw[2lEPTB;MUeuNlM{PCEQvF2=	NIfDfXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SK-MEL-2	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHC[41KSzVyPUG3MlMzOTNizszN	NETFVG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KURAMOCHI	NV\DXoNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTsdmZNUUN3ME2xO{4{QDl5IN88US=>	MnjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
IST-MEL1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPa[\|NbUUN3ME2xO{46OTh{IN88US=>	NVqwZZE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1793	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL2Z4VmUUN3ME2xPE4yPThzIN88US=>	Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HCC1395	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTF6LkW2NVEh\|ryP	Mk[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NUGC-3	NGTj[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPPVplzUUN3ME2xPE43PTh2IN88US=>	NFjTclU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BB65-RCC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHEbJlKSzVyPUG4MlY3QSEQvF2=	NEP0W4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
RMG-I	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn3enROUUN3ME2xPE44Ozh{IN88US=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LS-513	M2WwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUKzOXhlUUN3ME2xPE46OjJ6IN88US=>	M1;wN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
MFM-223	M3P1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3yZolFUUN3ME2xPU4xPzF4IN88US=>	NWHYfWtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H727	NHvVS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTF7LkOyPVUh\|ryP	NY\Kc\|djRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
KP-4	NF3UOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHSz[VJKSzVyPUG5Mlg2OzFizszN	MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NB13	NF;lSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvFTWM2OD1zOT64PFM6KM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
UACC-893	NV31NItuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPVTWM2OD1zOT65O\|U4KM7:TR?=	MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HT-1197	M3LDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJyLkK5OVgh\|ryP	Ml30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2029	M3vQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULFb5hjUUN3ME2yNE4{OjZ4IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
GI-ME-N	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXSzd45qUUN3ME2yNE4{Ozd\|IN88US=>	Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
OVCAR-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJyLkW4NlIh\|ryP	MoPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
HD-MY-Z	NHGwVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET6[ohKSzVyPUKxMlM3QTZizszN	MnWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NEHEfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3IVJdnUUN3ME2yNU43PzJ{IN88US=>	M1;hUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SCH	NIrNNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;hW2lEPTB;MkKuOFk3KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KARPAS-299	M4TJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXW4SJZuUUN3ME2yN{4{QDh5IN88US=>	NUTiT4RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1650	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjodI9QUUN3ME2yN{46OjRzIN88US=>	NVq5OZhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ACHN	M{CyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17veGlEPTB;MkSuOFY2PiEQvF2=	MnrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
M059J	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7pTWM2OD1{ND61OlM1KM7:TR?=	M4jpXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
AM-38	NXrQRXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXGe2VKSzVyPUK1MlQ5OSEQvF2=	M3fSTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
KG-1	NInufIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfnSldUUUN3ME2yOU42PDl2IN88US=>	MlP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-824	NFv3fINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3ITWM2OD1{NT61OVk6KM7:TR?=	NV\rOZBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1155	NEHOWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnjU41CUUN3ME2yOU42QDR5IN88US=>	MojvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H441	NIn3dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1f5cWlEPTB;MkWuO\|Q3PSEQvF2=	NF61d\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
J-RT3-T3-5	NX\YbVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37HV2lEPTB;Mk[uN\|AzPyEQvF2=	M3HyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
JEG-3	NIH5XI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\PNGlEPTB;Mk[uOlgxPSEQvF2=	Moe2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
RKO	M37Dcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4WxXGlEPTB;Mk[uO\|Y{OiEQvF2=	M3\1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
CAL-85-1	M4T5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPJRWJKSzVyPUK3MlIyOThizszN	NFnZRmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CAL-120	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTJ5Lk[5NVQh\|ryP	MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2452	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJ5Lke3NVYh\|ryP	M4C1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-H1395	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTJ5Lke4N\|Mh\|ryP	NFrveZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
KYSE-450	NWLienI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoftTWM2OD1{Nz65PFYzKM7:TR?=	MorrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
S-117	NWHUdWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTJ7LkO4OVch\|ryP	Mn3ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SW13	NHrBUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrZUW9KSzVyPUK5Mlg2OTlizszN	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
ES3	M4fHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zYSGlEPTB;M{CuN\|c{OyEQvF2=	M{LJTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
HCT-116	NEXEW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{K1TGlEPTB;M{CuOVU2PCEQvF2=	NVrqOWZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H1693	M1zzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTNyLkW5OFIh\|ryP	NETlWW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
VM-CUB-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELab4pKSzVyPUOwMlY1OTNizszN	MmPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H2170	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\Zd2lEPTB;M{GuOVc5PCEQvF2=	NULCd21rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
ALL-PO	NX;acJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH76c5JKSzVyPUOxMlg1OjhizszN	Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H661	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTN{LkC2NlMh\|ryP	NWnafVlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H2347	NVr6V\|lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTN{LkS4N\|ch\|ryP	NYi2e4g4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
FTC-133	M3XRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTN{LkewOkDPxE1?	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
COLO-829	M1nkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUG0OndKUUN3ME2zN{4{PDZ5IN88US=>	NV3MflVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
GOTO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHwZ4JDUUN3ME2zN{42OjV6IN88US=>	NWXvWHZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
YAPC	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN\|LkixOVkh\|ryP	NYTJfYFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
LCLC-103H	NHLYepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3OeFBMUUN3ME2zOE4yPjJ2IN88US=>	Mn3IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
SiHa	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUK1emNGUUN3ME2zOE4{QDF5IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LK-2	NFzKNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTN2LkW3NFgh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KP-N-YS	NGSyV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLZTY9KSzVyPUO0MlczODJizszN	M2jFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NCI-SNU-1	NH6zRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTN3LkG3PUDPxE1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
KNS-81-FD	M4\1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzCTWM2OD1\|NT62OlMh\|ryP	NWrHXVY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
SCC-9	NUnweWpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HsdmlEPTB;M{[uO\|E1PiEQvF2=	NGXvOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
SH-4	M3fiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\RTmlEPTB;M{[uO\|Mh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
HCC-1954	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHP3OFdKSzVyPUO3MlI4OjlizszN	NHXRd\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
BALL-1	NF;GT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\JPHNGUUN3ME2zO{42OzF4IN88US=>	NUPmSFVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
BE-13	M4X2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO2U25KSzVyPUO3MlcxOThizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
COLO-678	NVLJN\|ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXMTWM2OD1\|Nz65OFM4KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
SK-MEL-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTN6LkKzPVch\|ryP	NYPW[ZhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
OAW-28	M4e5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonDTWM2OD1\|OD62N\|kh\|ryP	NYHLeZdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
CAMA-1	NWLtVJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTN6Lkm2PVEh\|ryP	NUTnZXpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
C2BBe1	M{DBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTN7LkixPEDPxE1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
A3-KAW	NWDCbllzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTRyLkO2OlEh\|ryP	M3;xcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
SK-MEL-24	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{O1RmlEPTB;NECuOVk{OSEQvF2=	MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KYSE-140	NX3wcYxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\rSHdKUUN3ME20NE44OTZ3IN88US=>	NWXkd5B3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
MOLT-16	NVnBVIt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDhTWM2OD12MT6xOVM3KM7:TR?=	NFX5T3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
CFPAC-1	NFX2PGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvFTWM2OD12Mj61NlEyKM7:TR?=	M4r3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
NB14	M2Kyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVn0ZYNDUUN3ME20Nk44ODJ5IN88US=>	NH;4VVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
COLO-792	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHRTWM2OD12Mj64PVYyKM7:TR?=	M2LvTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUzOTh3MT:nQnNCVkeHUkyvZV4>
RH-1	M1zPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzRXZg4UUN3ME20N{41QDN4IN88US=>	NXvFW4pMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
NCI-H522	NIXSVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;ZXoZOUUN3ME20OE4{PTZ6IN88US=>	NFzUdJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,
Ca-Ski	M{S5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoflTWM2OD12ND64NVE1KM7:TR?=	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
KGN	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjse5dKSzVyPUS4MlMxPjNizszN	NV\JTHlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
UACC-62	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTyN2JKSzVyPUS4MlQxPzJizszN	Mo\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVIyQDVzLze+V2FPT0WUPD;hQi=>
NCI-H358	M3u2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLWTWM2OD12OT6zNFE5KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NlE5PTFxJ{7TRW5ITVJ:L3G+
LS-411N	NUj0doh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIO2cmlKSzVyPUS5MlMyOThizszN	NV\GVpRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTJzOEWxM{c,W0GQR1XSQE9iRg>?
IST-MES1	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGL6RZNKSzVyPUS5MlU3OjVizszN	NGGzOJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2OjF6NUGvK\|5USU6JRWK8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RG7321
Smiles	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin (KY 12420, SL-2052) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)